



Xellia Pharmaceuticals secures \$430m financing to support long-term growth

Funding will provide continued investment in manufacturing operations, contribute to expanding capacity and sustainability of facilities producing vital anti-infectives. In addition, the credit facility will support Xellia's efforts to combat AMR and ensure antibiotic stewardship and extend a regional, reliable supply of treatments where patients need them around the world.

Copenhagen, Denmark, 08 December 2022 – Xellia Pharmaceuticals ('Xellia' or the 'Group'), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, has secured long term financing of \$430m to support its growth strategy.

The \$430m funding is provided by Xellia's existing banking partners, Danske Bank and Nordea, and will be used to continue Xellia's investment in its manufacturing facilities. This will allow for capacity expansion and ensure the long-term sustainability of manufacturing of critical anti-infective therapies and differentiated critical care products at its facilities in Europe, the U.S. and Asia.

Securing the manufacture of Xellia's portfolio of anti-infectives is a vital part of Xellia's efforts to combat the growing challenge of antimicrobial resistance and will help support the Company's responsible antibiotic stewardship goals. The funding is also important to ensuring access to these crucial medicines when patients are in need around the world, through Xellia's reliable, regional supply.

Additionally, the proceeds will be used to continue Xellia's investment in R&D and innovation in its core area of anti-infectives and will also further support the development of the Company's Premix franchise, which focuses on the development of critical hospital medicines, provided in a room-temperature stable, ready-to-use form with the potential to improve safety, speed of use and reduce dosing errors.

Sustainability has long been at the forefront of Xellia's values, and this latest funding comes with commitments to key ESG targets, developed with its investors to ensure that they can be delivered in a meaningful way. These targets will be measured and reported on annually, demonstrating Xellia's commitment to its ESG responsibilities.

Carl-Åke Carlsson, CEO of Xellia Pharmaceuticals, commented:

"This financing enables Xellia to drive forward the development and innovation which keeps us at the forefront of anti-infective and critical care manufacturing and ensures a reliable supply of these vital medicines around the world.

"Through the funding, we are also emphasizing our commitment to our ESG goals, which we believe strongly in and have been delivering on for many years. We are now well positioned for our future growth, and we look forward to expanding manufacturing at our locations worldwide."

-Ends-



About Xellia Pharmaceuticals:

Xellia Pharmaceuticals is a specialty pharmaceutical company providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions. The Company has an extensive history in developing, manufacturing, and commercializing anti-infective products, including Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Forms, where the majority are injectable drug products.

Committed to providing security and consistency in supply of critical care therapies, Xellia holds a global vertically integrated supply chain, where the Company continuously works to deliver on this commitment through offering multiple sources of in-house production of its APIs and drug products, integrated with Xellia's R&D centers of excellence. Through innovation and with the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia Pharmaceuticals is wholly owned by Novo Holdings A/S and employs a dedicated team of more than 1,700 people.

For more information, please contact:

Xellia Pharmaceuticals

Carl-Åke Carlsson, CEO

Tel: +45 32 64 55 00

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Rozi Morris / Manisha Kuttetira

Tel: +44 (0) 20 7457 2020

Email: xellia@instinctif.com